help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daughaday, W. H.
Right arrow Articles by Kapadia, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daughaday, W. H.
Right arrow Articles by Kapadia, M.

Journal of Clinical Endocrinology & Metabolism, Vol 53, 289-294, Copyright © 1981 by Endocrine Society

ARTICLES

Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia

WH Daughaday, B Trivedi and M Kapadia

A radioreceptor assay for insulin-like growth factor II (IGF-II) is described in which [125I]IGF-II is bound by rat placental membranes. IGF-I and other insulin-related peptides have less than 1% of the potency of IGF-II in displacing [125I]-IGF-II. IGF-II is extracted from its serum binding protein with a simple acid-ethanol step. After neutralization with Tris base, the extract is introduced directly into the radioreceptor assay. Results are expressed in terms of a reference serum with an assigned potency of 1 U/ml. By this method, serum from normal adults, 20-69 yr of age, had a mean (+/-SE)IGF-II activity of 0.73 +/- 0.03; higher concentrations were noted in adults more than 70 years of age (1.05 +/- 0.05), in cord serum (1.55 +/- 0.24), and in short children with normal GH secretion (0.88 +/- 0.42). In hypopituitary dwarfism, serum IGF-II activity was reduced (0.50 +/- 0.05), but in acromegaly, it was not increased (0.77 +/- 0.06). In 10 of 14 serum samples from patients with tumor-related hypoglycemia, the IGF-II exceeded the normal 95.5% confidence limits. In 8 of these sera, IGF-I by RIA was low, and in 5, it was essentially unmeasurable. These results with a new radioreceptor assay for IGF-II provide additional evidence that the regulation of this serum peptide differs from that of IGF-I.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. D. Hoang, X. Zhang, P. D. Scott, T. J. Guillaume, M. A. Maddaus, D. Yee, and R. A. Kratzke
Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells: Association with Distinct Malignant Phenotypes
Cancer Res., October 15, 2004; 64(20): 7479 - 7485.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
R. C Stein
Nonmetastatic manifestations of malignancy: hormonal
Palliative Medicine, July 1, 1989; 3(3): 189 - 196.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society